Challenges to congenital genetic disorders with "RNA-targeting" chemical compounds

Pharmacology and Therapeutics

Volumn 134, Issue 3, 2012, Pages 298-305

  Ogawa, Yasushi ^a   Hagiwara, Masatoshi ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Denys Drash Syndrome; Down syndrome; Duchenne muscular dystrophy; INDY; SRPIN340; TG003

Indexed keywords

1 (3 ETHYL 5 HYDROXY 2(3H) BENZOTHIAZOYLIDENE) 2 PROPANONE; ATALUREN; BENZOTHIAZOLE DERIVATIVE; DNA; DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1A; HARMINE; MESSENGER RNA; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RNA; SRPIN 340; TG 003; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ALZHEIMER DISEASE; DENYS DRASH SYNDROME; DOWN SYNDROME; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DUCHENNE MUSCULAR DYSTROPHY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE TARGETING; HUMAN; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RNA TARGETING; STOP CODON;

DENYS-DRASH SYNDROME; DOWN SYNDROME; HUMANS; MODELS, GENETIC; MOLECULAR TARGETED THERAPY; MUSCULAR DYSTROPHIES; PROTEIN KINASE INHIBITORS; TRANSCRIPTION, GENETIC;

EID: 84859787938     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.02.001     Document Type: Review

References (84)

1. Ahn, K. J., Jeong, H. K., Choi, H. S., Ryoo, S. R., Kim, Y. J., Goo, J. S., Choi, S. Y., Han, J. S., Ha, I., & Song, W. J. (2006). DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects. Neurobiol Dis 22, 463-472. (Pubitemid 43832120)
2. Altafaj, X., Dierssen, M., Baamonde, C., Marti, E., Visa, J., Guimera, J., Oset, M., Gonzalez, J. R., Florez, J., Fillat, C., & Estivill, X. (2001). Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum Mol Genet 10, 1915-1923. (Pubitemid 32910536)
3. Altafaj, X., Ortiz-Abalia, J., Fernandez, M., Potier, M. C., Laffaire, J., Andreu, N., Dierssen, M., Gonzalez-Garcia, C., Cena, V., Marti, E., & Fillat, C. (2008). Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome. Neurobiol Dis 32, 377-384.
4. Amin, E. M., Oltean, S., Hua, J., Gammons, M. V., Hamdollah-Zadeh, M., Welsh, G. I., Cheung, M., Ni, L., Kase, S., Rennel, E. S., Symonds, K. E., Nowak, D. G., Pokora-Royer, B., Saleem, M. A., Hagiwara, M., Schumacher, V. A., Harper, S. J., Hinton, D. R., Bates, D. O., & Ladomery, M. R. (2011). WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell 20, 768-780.
5. Antonarakis, S. E., & Epstein, C. J. (2006). The challenge of Down syndrome. Trends Mol Med 12, 473-479. (Pubitemid 44441997)
6. Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H., Klevernic, I., Arthur, J. S., Alessi, D. R., & Cohen, P. (2007). The selectivity of protein kinase inhibitors: a further update. Biochem J 408, 297-315.
7. Becker, W., & Sippl, W. (2011). Activation, regulation, and inhibition of DYRK1A. FEBS J 278, 246-256.
8. Becker, W., Weber, Y., Wetzel, K., Eirmbter, K., Tejedor, F. J., & Joost, H. G. (1998). Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases. J Biol Chem 273, 25893-25902. (Pubitemid 28475820)
9. Branchi, I., Bichler, Z., Minghetti, L., Delabar, J. M., Malchiodi-Albedi, F., Gonzalez, M. C., Chettouh, Z., Nicolini, A., Chabert, C., Smith, D. J., Rubin, E. M., Migliore-Samour, D., & Alleva, E. (2004). Transgenic mouse in vivo library of human Down syndrome critical region 1: association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration. J Neuropathol Exp Neurol 63, 429-440. (Pubitemid 38669664)
10. Coyle, J. T., Oster-Granite, M. L., & Gearhart, J. D. (1986). The neurobiologic consequences of Down syndrome. Brain Res Bull 16, 773-787. (Pubitemid 16041613)
11. de Graaf, K., Czajkowska, H., Rottmann, S., Packman, L. C., Lilischkis, R., Luscher, B., & Becker, W. (2006). The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site. BMC Biochem 7, 7.
12. Ding, S., Shi, J., Qian, W., Iqbal, K., Grundke-Iqbal, I., Gong, C.X., & Liu, F. in press. Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A. Neurobiol Aging.
13. Dowjat, W. K., Adayev, T., Kuchna, I., Nowicki, K., Palminiello, S., Hwang, Y. W., & Wegiel, J. (2007). Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome. Neurosci Lett 413, 77-81. (Pubitemid 46149186)
14. Dreyfuss, G., Kim, V. N., & Kataoka, N. (2002). Messenger-RNA-binding proteins and the messages they carry. Nat Rev Mol Cell Biol 3, 195-205.
15. Ferrer, I., Barrachina, M., Puig, B., Martinez de Lagran, M., Marti, E., Avila, J., & Dierssen, M. (2005). Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol Dis 20, 392-400. (Pubitemid 41476265)
16. Fukuhara, T., Hosoya, T., Shimizu, S., Sumi, K., Oshiro, T., Yoshinaka, Y., Suzuki, M., Yamamoto, N., Herzenberg, L. A., Herzenberg, L. A., & Hagiwara, M. (2006). Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc Natl Acad Sci U S A 103, 11329-11333. (Pubitemid 44156517)
17. Gockler, N., Jofre, G., Papadopoulos, C., Soppa, U., Tejedor, F. J., & Becker, W. (2009). Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J 276, 6324-6337.
18. Gui, J. F., Lane, W. S., & Fu, X. D. (1994). A serine kinase regulates intracellular localization of splicing factors in the cell cycle. Nature 369, 678-682. (Pubitemid 24199476)
19. Guimera, J., Casas, C., Estivill, X., & Pritchard, M. (1999). Human minibrain homologue (MNBH/DYRK1): characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome. Genomics 57, 407-418. (Pubitemid 29239228)
20. Guimera, J., Casas, C., Pucharcos, C., Solans, A., Domenech, A., Planas, A. M., Ashley, J., Lovett, M., Estivill, X., & Pritchard, M. A. (1996). A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region. Hum Mol Genet 5, 1305-1310. (Pubitemid 26335848)
21. Hagiwara, M. (2005). Alternative splicing: a new drug target of the post-genome era. Biochim Biophys Acta 1754, 324-331.
22. Hammerle, B., Carnicero, A., Elizalde, C., Ceron, J., Martinez, S., & Tejedor, F. J. (2003). Expression patterns and subcellular localization of the Down syndrome candidate protein MNB/DYRK1A suggest a role in late neuronal differentiation. Eur J Neurosci 17, 2277-2286. (Pubitemid 36793737)
23. Hammerle, B., Elizalde, C., & Tejedor, F. J. (2008). The spatio-temporal and subcellular expression of the candidate Down syndrome gene Mnb/Dyrk1A in the developing mouse brain suggests distinct sequential roles in neuronal development. Eur J Neurosci 27, 1061-1074. (Pubitemid 351432344)
24. Karakama, Y., Sakamoto, N., Itsui, Y., Nakagawa, M., Tasaka-Fujita, M., Nishimura- Sakurai, Y., Kakinuma, S., Oooka, M., Azuma, S., Tsuchiya, K., Onogi, H., Hagiwara, M., &Watanabe,M. (2010). Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase. Antimicrob Agents Chemother 54, 3179-3186.
25. Kay, M. A. (2011). State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 12, 316-328.
26. Kida, E., Walus, M., Jarzabek, K., Palminiello, S., Albertini, G., Rabe, A., Hwang, Y. W., & Golabek, A. A. (2011). Formof dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A nonphosphorylated at tyrosine 145 and 147 is enriched in the nuclei of astroglial cells, adult hippocampal progenitors, and some cholinergic axon terminals. Neuroscience 195, 112-127.
27. Kim, H., Sablin, S. O., & Ramsay, R. R. (1997). Inhibition of monoamine oxidase A by beta-carboline derivatives. Arch Biochem Biophys 337, 137-142. (Pubitemid 27198065)
28. Kimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., Hashimoto, R., Tanaka, T., Kudo, T., Yamagata, H., Tabara, Y., Miki, T., Akatsu, H., Kosaka, K., Funakoshi, E., Nishitomi, K., Sakaguchi, G., Kato, A., Hattori, H., Uema, T., & Takeda, M. (2007). The DYRK1A gene, encoded in chromosome 21 Downsyndromecritical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet 16, 15-23. (Pubitemid 46152541)
29. Koenig, M., Monaco, A. P., & Kunkel, L. M. (1988). The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 53, 219-228.
30. Korbel, J. O., Tirosh-Wagner, T., Urban, A. E., Chen, X. N., Kasowski, M., Dai, L., Grubert, F., Erdman, C., Gao, M. C., Lange, K., Sobel, E. M., Barlow, G. M., Aylsworth, A. S., Carpenter, N. J., Clark, R. D., Cohen, M. Y., Doran, E., Falik-Zaccai, T., Lewin, S. O., Lott, I. T., McGillivray, B. C., Moeschler, J. B., Pettenati, M. J., Pueschel, S. M., Rao, K. W., Shaffer, L. G., Shohat, M., Van Riper, A. J., Warburton, D., Weissman, S., Gerstein, M. B., Snyder, M., & Korenberg, J. R. (2009). The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc Natl Acad Sci U S A 106, 12031-12036.
31. Ku, C. S., Naidoo, N., & Pawitan, Y. (2011). Revisiting Mendelian disorders through exome sequencing. Hum Genet 129, 351-370.
32. Kuroyanagi, N., Onogi, H., Wakabayashi, T., & Hagiwara, M. (1998). Novel SR-proteinspecific kinase, SRPK2, disassembles nuclear speckles. Biochem Biophys Res Commun 242, 357-364. (Pubitemid 28412432)
33. Kuyumcu-Martinez, N. M., Wang, G. S., & Cooper, T. A. (2007). Increased steady-state in levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell 28, 68-78. (Pubitemid 47531966)
34. La Spada, A. R., Paulson, H. L., & Fischbeck, K. H. (1994). Trinucleotide repeat expansion in neurological disease. Ann Neurol 36, 814-822. (Pubitemid 24370919)
35. Laguna, A., Aranda, S., Barallobre, M. J., Barhoum, R., Fernandez, E., Fotaki, V., Delabar, J. M., de la Luna, S., de la Villa, P., & Arbones, M. L. (2008). The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development. Dev Cell 15, 841-853.
36. Lee, J. E., & Cooper, T. A. (2009). Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans 37, 1281-1286.
37. Licatalosi, D. D., & Darnell, R. B. (2010). RNA processing and its regulation: global insights into biological networks. Nat Rev Genet 11, 75-87.
38. Liu, F., & Gong, C. X. (2008). Tau exon 10 alternative splicing and tauopathies. Mol Neurodegener 3, 8.
39. Liu, F., Liang, Z., Wegiel, J., Hwang, Y. W., Iqbal, K., Grundke-Iqbal, I., Ramakrishna, N., & Gong, C. X. (2008). Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J 22, 3224-3233.
40. Long, J. C., & Caceres, J. F. (2009). The SR protein family of splicing factors: master regulators of gene expression. Biochem J 417, 15-27.
41. Mankodi, A., Logigian, E., Callahan, L., McClain, C., White, R., Henderson, D., Krym, M., & Thornton, C. A. (2000). Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 289, 1769-1772.
42. Martinez de Lagran, M., Altafaj, X., Gallego, X., Marti, E., Estivill, X., Sahun, I., Fillat, C., & Dierssen, M. (2004). Motor phenotypic alterations in TgDyrk1a transgenic mice implicate DYRK1A in Down syndrome motor dysfunction. Neurobiol Dis 15, 132-142. (Pubitemid 38134388)
43. Mattick, J. S., & Mehler, M. F. (2008). RNA editing, DNA recoding and the evolution of human cognition. Trends Neurosci 31, 227-233.
44. Miller, J. W., Urbinati, C. R., Teng-umnuay, P., Stenberg, M. G., Byrne, B. J., Thornton, C. A., & Swanson, M. S. (2000). Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J 19, 4439-4448.
45. Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988). An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2, 90-95.
46. Muntoni, F., Torelli, S., & Ferlini, A. (2003). Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2, 731-740. (Pubitemid 37443515)
47. Muntoni, F., & Wood, M. J. (2011). Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov 10, 621-637.
48. Muraki, M., Ohkawara, B., Hosoya, T., Onogi, H., Koizumi, J., Koizumi, T., Sumi, K., Yomoda, J., Murray, M. V., Kimura, H., Furuichi, K., Shibuya, H., Krainer, A. R., Suzuki, M., & Hagiwara, M. (2004). Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 279, 24246-24254. (Pubitemid 38725286)
49. Nishida, A., Kataoka, N., Takeshima, Y., Yagi, M., Awano, H., Ota, M., Itoh, K., Hagiwara, M., & Matsuo, M. (2011). Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat Commun 2, 308.
50. Nowak, D. G., Amin, E. M., Rennel, E. S., Hoareau-Aveilla, C., Gammons, M., Damodoran, G., Hagiwara, M., Harper, S. J., Woolard, J., Ladomery, M. R., & Bates, D. O. (2010). Regulation of vascular endothelial growth factor (VEGF) splicing from proangiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem 285, 5532-5540.
51. O'Doherty, A., Ruf, S., Mulligan, C., Hildreth, V., Errington, M. L., Cooke, S., Sesay, A., Modino, S., Vanes, L., Hernandez, D., Linehan, J. M., Sharpe, P. T., Brandner, S., Bliss, T. V., Henderson, D. J., Nizetic, D., Tybulewicz, V. L., & Fisher, E. M. (2005). An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 309, 2033-2037. (Pubitemid 41362316)
52. Ogawa, Y., Nonaka, Y., Goto, T., Ohnishi, E., Hiramatsu, T., Kii, I., Yoshida, M., Ikura, T., Onogi, H., Shibuya, H., Hosoya, T., Ito, N., & Hagiwara, M. (2010). Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat Commun 1, 86.
53. Olson, L. E., Roper, R. J., Sengstaken, C. L., Peterson, E. A., Aquino, V., Galdzicki, Z., Siarey, R., Pletnikov, M., Moran, T. H., & Reeves, R. H. (2007). Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. Hum Mol Genet 16, 774-782. (Pubitemid 47061624)
54. Ortiz-Abalia, J., Sahun, I., Altafaj, X., Andreu, N., Estivill, X., Dierssen, M., & Fillat, C. (2008). Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome. Am J Hum Genet 83, 479-488.
55. Philips, A. V., Timchenko, L. T., & Cooper, T. A. (1998). Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 280, 737-741. (Pubitemid 28243348)
56. Qian, W., Liang, H., Shi, J., Jin, N., Grundke-Iqbal, I., Iqbal, K., Gong, C. X., & Liu, F. (2011). Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A. Nucleic Acids Res 39, 6161-6171.
57. Qiu, Y., Hoareau-Aveilla, C., Oltean, S., Harper, S. J., & Bates, D. O. (2009). The antiangiogenic isoforms of VEGF in health and disease. Biochem Soc Trans 37, 1207-1213.
58. Rajman, I. (2008). PK/PD modelling and simulations: utility in drug development. Drug Discov Today 13, 341-346.
59. Roubertoux, P. L., & Carlier, M. (2010). Mouse models of cognitive disabilities in trisomy 21 (Down syndrome). Am J Med Genet C Semin Med Genet 154C, 400-416.
60. Roy, A., McDonald, P. R., Sittampalam, S., & Chaguturu, R. (2010). Open access high throughput drug discovery in the public domain: a Mount Everest in the making. Curr Pharm Biotechnol 11, 764-778.
61. Ryoo, S. R., Cho, H. J., Lee, H. W., Jeong, H. K., Radnaabazar, C., Kim, Y. S., Kim, M. J., Son, M. Y., Seo, H., Chung, S. H., & Song, W. J. (2008). Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease. J Neurochem 104, 1333-1344. (Pubitemid 351293338)
62. Ryoo, S. R., Jeong, H. K., Radnaabazar, C., Yoo, J. J., Cho, H. J., Lee, H. W., Kim, I. S., Cheon, Y. H., Ahn, Y. S., Chung, S. H., & Song, W. J. (2007). DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J Biol Chem 282, 34850-34857. (Pubitemid 350232475)
63. Sebrie, C., Chabert, C., Ledru, A., Guedj, F., Po, C., Smith, D. J., Rubin, E., Rivals, I., Beloeil, J. C., Gillet, B., & Delabar, J. M. (2008). Increased dosage of DYRK1A and brain volumetric alterations in a YAC model of partial trisomy 21. Anat Rec (Hoboken) 291, 254-262.
64. Shepard, P. J., & Hertel, K. J. (2009). The SR protein family. Genome Biol 10, 242.
65. Sherman, S. L., Allen, E. G., Bean, L. H., & Freeman, S. B. (2007). Epidemiology of Down syndrome. Ment Retard Dev Disabil Res Rev 13, 221-227. (Pubitemid 47613276)
66. Shi, J., Zhang, T., Zhou, C., Chohan, M. O., Gu, X., Wegiel, J., Zhou, J., Hwang, Y. W., Iqbal, K., Grundke-Iqbal, I., Gong, C. X., & Liu, F. (2008). Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome. J Biol Chem 283, 28660-28669.
67. Shindoh, N., Kudoh, J., Maeda, H., Yamaki, A., Minoshima, S., Shimizu, Y., & Shimizu, N. (1996). Cloning of a human homolog of the Drosophila minibrain/rat Dyrk gene from "the Down syndrome critical region" of chromosome 21. Biochem Biophys Res Commun 225, 92-99. (Pubitemid 26285401)
68. Smith, D. J., Stevens,M. E., Sudanagunta, S. P., Bronson, R. T., Makhinson,M.,Watabe, A. M., O'Dell, T. J., Fung, J., Weier, H. U., Cheng, J. F., & Rubin, E.M. (1997). Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat Genet 16, 28-36. (Pubitemid 27198153)
69. Song, W. J., Sternberg, L. R., Kasten-Sportes, C., Keuren, M. L., Chung, S. H., Slack, A. C., Miller, D. E., Glover, T. W., Chiang, P. W., Lou, L., & Kurnit, D. M. (1996). Isolation of human and murine homologues of the Drosophila minibrain gene: human homologuemaps to 21q22.2 in the Down syndrome "critical region". Genomics 38, 331-339. (Pubitemid 27030122)
70. Tejedor, F. J., & Hammerle, B. (2011). MNB/DYRK1A as a multiple regulator of neuronal development. FEBS J 278, 223-235.
71. Thomas, C. J., Auld, D. S., Huang, R., Huang, W., Jadhav, A., Johnson, R. L., Leister, W., Maloney, D. J., Marugan, J. J., Michael, S., Simeonov, A., Southall, N., Xia, M., Zheng, W., Inglese, J., & Austin, C. P. (2009). The pilot phase of the NIH Chemical Genomics Center. Curr Top Med Chem 9, 1181-1193.
72. Toiber, D., Azkona, G., Ben-Ari, S., Toran, N., Soreq, H., & Dierssen, M. (2010). Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations. Neurobiol Dis 40, 348-359.
73. Vilardell, M., Rasche, A., Thormann, A., Maschke-Dutz, E., Perez-Jurado, L. A., Lehrach, H., & Herwig, R. (2011). Meta-analysis of heterogeneous Down Syndrome data reveals consistent genome-wide dosage effects related to neurological processes. BMC Genomics 12, 229.
74. Wagner, K. R., Hamed, S., Hadley, D. W., Gropman, A. L., Burstein, A. H., Escolar, D. M., Hoffman, E. P., & Fischbeck, K. H. (2001). Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 49, 706-711. (Pubitemid 32530236)
75. Wang, G. S., Kuyumcu-Martinez, M. N., Sarma, S., Mathur, N., Wehrens, X. H. T., & Cooper, T. A. (2009). PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest 119, 3797-3806.
76. Warf, M. B., Nakamori, M., Matthys, C. M., Thornton, C. A., & Berglund, J. A. (2009). Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci U S A 106, 18551-18556.
77. Wegiel, J., Dowjat, K., Kaczmarski, W., Kuchna, I., Nowicki, K., Frackowiak, J., Mazur Kolecka, B., Wegiel, J., Silverman, W. P., Reisberg, B., Deleon, M., Wisniewski, T., Gong, C. X., Liu, F., Adayev, T., Chen-Hwang, M. C., & Hwang, Y. W. (2008). The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathol 116, 391-407.
78. Wegiel, J., Gong, C. X., & Hwang, Y. W. (2011). The role of DYRK1A in neurodegenerative diseases. FEBS J 278, 236-245.
79. Welch, E. M., Barton, E. R., Zhuo, J., Tomizawa, Y., Friesen, W. J., Trifillis, P., Paushkin, S., Patel, M., Trotta, C. R., Hwang, S., Wilde, R. G., Karp, G., Takasugi, J., Chen, G., Jones, S., Ren, H., Moon, Y. C., Corson, D., Turpoff, A. A., Campbell, J. A., Conn, M. M., Khan, A., Almstead, N. G., Hedrick, J., Mollin, A., Risher, N., Weetall, M., Yeh, S., Branstrom, A. A., Colacino, J. M., Babiak, J., Ju, W. D., Hirawat, S., Northcutt, V. J., Miller, L. L., Spatrick, P., He, F., Kawana, M., Feng, H., Jacobson, A., Peltz, S. W., & Sweeney, H. L. (2007). PTC124 targets genetic disorders caused by nonsensemutations. Nature 447, 87-91. (Pubitemid 46685839)
80. Wiseman, F. K., Alford, K. A., Tybulewicz, V. L., & Fisher, E. M. (2009). Down syndrome -recent progress and future prospects. Hum Mol Genet 18, R75-R83.
81. Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985). Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 17, 278-282. (Pubitemid 15136603)
82. Woods, Y. L., Cohen, P., Becker, W., Jakes, R., Goedert, M., Wang, X., & Proud, C. G. (2001). The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem J 355, 609-615. (Pubitemid 32434076)
83. Yomoda, J., Muraki, M., Kataoka, N., Hosoya, T., Suzuki, M., Hagiwara, M., & Kimura, H. (2008). Combination of Clk family kinase and SRp75 modulates alternative splicing of Adenovirus E1A. Genes Cells 13, 233-244. (Pubitemid 351292279)
84. Yu, T., Li, Z., Jia, Z., Clapcote, S. J., Liu, C., Li, S., Asrar, S., Pao, A., Chen, R., Fan, N., Carattini-Rivera, S., Bechard, A. R., Spring, S., Henkelman, R. M., Stoica, G., Matsui, S., Nowak, N. J., Roder, J. C., Chen, C., Bradley, A., & Yu, Y. E. (2010). A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum Mol Genet 19, 2780-2791.